Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 10;2(1):vdaa115. doi: 10.1093/noajnl/vdaa115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — The antiglioma activity of mutated E protein. (A) Representative clonogenic survival plates and (B) quantifications of clonogenic survival of RFP-dnE47 and RFP-E47 transduced LN229 cells after indicated treatments. (C) Cytotoxicity assay of RFP-dnE47 and RFP-E47 transduced LNZ308 cells after indicated treatments. As dnE47 induction alone already strongly curtailed cell survival (dnE47 vs. RT P = .0384*, dnE47 vs. CT P < .0001****) resp. increased cytotoxic cell death (dnE47 vs. RT P < .0001****, dnE47 vs. CT P < .0001****) significantly better than chemo- or radiotherapy, neither preceding (RT-CT/DOX) nor subsequent (DOX/RT-CT) radiochemotherapy led to a consistent significant additional benefit. (D) Kaplan -Meier curves.